Insider Buying: vTv Therapeutics Inc (NASDAQ:VTVT) Major Shareholder Acquires 1,212,121 Shares of Stock

Share on StockTwits

vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman acquired 1,212,121 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was bought at an average price of $1.65 per share, for a total transaction of $1,999,999.65. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

vTv Therapeutics stock opened at $1.43 on Thursday. The firm has a market cap of $67.93 million, a price-to-earnings ratio of -2.07 and a beta of -3.70. vTv Therapeutics Inc has a 52-week low of $0.68 and a 52-week high of $6.09. The business’s 50 day simple moving average is $1.53.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.26) earnings per share for the quarter. The firm had revenue of $0.92 million for the quarter. On average, analysts anticipate that vTv Therapeutics Inc will post -0.59 EPS for the current fiscal year.

Several brokerages have recently commented on VTVT. ValuEngine lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. HC Wainwright began coverage on shares of vTv Therapeutics in a report on Thursday, May 30th. They issued a “buy” rating and a $5.00 price objective on the stock. Northland Securities set a $3.00 price objective on shares of vTv Therapeutics and gave the stock a “hold” rating in a report on Monday, March 18th. Finally, Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd.

Several hedge funds and other institutional investors have recently bought and sold shares of VTVT. Barclays PLC raised its holdings in shares of vTv Therapeutics by 366.7% during the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 22,000 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $186,000. Finally, Wedbush Securities Inc. acquired a new stake in shares of vTv Therapeutics during the first quarter worth $30,000. 3.94% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Featured Article: Trade Deficit

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

William I. Jacobs Sells 600 Shares of Global Payments Inc  Stock
William I. Jacobs Sells 600 Shares of Global Payments Inc Stock
Stewart Butterfield Sells 2,500 Shares of Slack  Stock
Stewart Butterfield Sells 2,500 Shares of Slack Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp.  Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp. Stock
Insider Buying: ALS Ltd  Insider Buys 14,983 Shares of Stock
Insider Buying: ALS Ltd Insider Buys 14,983 Shares of Stock
Opko Health Inc.  CEO Purchases $106,000.00 in Stock
Opko Health Inc. CEO Purchases $106,000.00 in Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc  Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc Stock


© 2006-2019 Ticker Report